ProCE Banner Activity

Lenalidomide + Epoetin alfa Restores Erythropoietin Sensitivity in Patients With Lower-Risk Myelodysplastic Syndromes

Slideset Download
Conference Coverage
Lenalidomide can restore epoetin alfa sensitivity in lower-risk MDS patients refractory or unresponsive to erythropoiesis stimulating agents.

Released: December 06, 2016

Expiration: December 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen